Tag: VEITH 2023

“We still have a lot more work to do”: Professor of...

 “I don’t reflect back enough on how much things have changed,” Cynthia Shortell (Durham, USA) tells Vascular News at the 2023 VEITHsymposium (14–18 November,...

Active sac management represents “step forward” for EVAR

 "Despite significant technological improvements since its inception, endovascular repair of abdominal aortic aneurysms (AAAs) is still associated with some of the same problems we...

LIMIT trial: Could metformin be first-ever medical treatment that is effective...

 There is a global interest in assessing whether Metformin, which has a long track record of safety and efficacy, is relatively inexpensive and is...

Deep vein arterialisation: “A real advance” for treatment of ‘no-option’ CLTI

 Daniel Clair (Vanderbilt University Medical Center, Nashville, USA) speaks to Vascular News at this year’s VEITHsymposium (14–18 November, New York, USA) on deep vein...
TRANSCEND

TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of...

Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics' TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18...

Twelve-month first-in-human data from Xeltis’ aXess haemodialysis vascular conduit trial presented...

Xeltis has announced "highly encouraging" 12-month results from its first-in-human (FIH) aXess vascular conduit trial. The data were presented by Frans Moll (University Medical...
technology

Randomised trial set to elucidate value of image fusion technology for...

An ongoing UK National Institute for Health and Care Research (NIHR)-funded randomised controlled trial seeks to illuminate the value of an image fusion guidance...
SWING

Two-year SWING data “continue to show promise” for sirolimus DCB in...

Two-year data from the SWING trial, a first-in-human study of the safety and performance of the Sundance sirolimus drug-coated balloon (DCB; Surmodics), have been...

Getinge announces US commercial availability of iCast covered stent system for...

Getinge has announced commercial availability of the iCast covered stent system in the USA for the treatment of iliac arterial occlusive disease. In March...